Sarepta will resume gene therapy shipments after FDA review of recent patient death
The Food and Drug Administration said it recommended lifting the hold for young patients with Duchenne's muscular dystrophy who are still able to walk. Regulators had requested the pause after the
deaths of two older teenagers
who were taking the therapy. The FDA also said in a statement it determined that a recently reported death of an 8-year-old boy was unrelated to the therapy.
Company shares surged more than 16% after the announcement to $13.86 in afterhours trading. The jump is the latest in a series of drastic stock movements triggered by changing fortunes for the company's best-selling product.
Elevidys is the first gene therapy
approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects boys and young men, resulting in early death. It received accelerated approval in 2023 for a narrow range of young patients and was expanded last year for use in older patients, including those who can no longer walk.
The FDA decision Monday 'significantly improves Elevidys' sales outlook in the near-term,' Jefferies analyst Andrew Tsai told investors, in a note after the announcement. 'The street will feel relieved about the situation, suggesting meaningful stock upside potential.'
Sarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver injury, a known side effect of the treatment. The FDA then requested a pause in shipments of the drug after the death of a third patient taking a different Sarepta therapy.
FDA officials have suggested the company will need to provide new study data on safety to resume Elevidys' use in older patients.
'The FDA will continue to work with the sponsor regarding non-ambulatory patients, which remains subject to a voluntary hold, following two deaths,' FDA said in its statement.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Popular sweetener recalled over labeling mix-up as FDA issues warning
Double check your sweetener before adding it to your coffee or tea. NuNaturals, a company known for its zero-sugar sweeteners, baking items, and other goods, issued a voluntary recall of certain Organic Monk Fruit and Stevia sweeteners in July. A labeling mix-up revealed that bottles labeled as Stevia were filled with the monk fruit sweetener and vice versa. Now, the recall has been elevated by the FDA to a Class II, the second-highest risk level. A Class II recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. The mislabeling can pose a serious health risk to those allergic to ragweed and related plants, as they may have a sensitivity to stevia. Monk fruit allergies, though rare according to WebMD, are also possible. The severity of an allergic reaction can vary from mild irritation to potential complications including anaphylaxis, resulting in respiratory problems. NuNaturals said 78 bottles of the Monk Fruit and 78 bottles of the Stevia sweeteners were affected by the recall. Affected Pure Monk Fruit Sweetener bottles have the UPC code: 7 39223 00187 and lot number: 25104S. Organic Pure Stevia bottles have the UPC code: 7 39223 00204 0 and lot number: 25104S. Specific information on where the mislabeled bottles were sold was not made available. The NuNautrals recall is the latest in a string of mislabelling recalls affecting consumers. In late July, High Noon Hard Seltzers were recalled over a labeling error. Some cans, filled with High Noon Vodka Seltzer, were mislabeled as the non-alcoholic Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition. As a result, drinking the beverage in these cans can result in unintentional alcohol consumption. However, no illnesses or adverse events have been reported to date. Prior to that, a voluntary recall was initiated July 14 by food ingredient company Bunge North America, affecting 1,800 cases of its NH European Style Butter Blend, which did not declare milk as an allergen on the label. Over 64,000 pounds of the contaminated butter was sent to 12 distribution centers located throughout the U.S., as well as a single distribution center located in the Dominican Republic. Affected cases were packaged in white paperboard and contained 36 blocks.
The Hill
12 minutes ago
- The Hill
RFK Jr. accepted flu shot recommendations for children
Health and Human Services Secretary Robert F. Kennedy Jr. accepted a vote by a federal immunization panel to recommend the influenza vaccine for children, pregnant women and all adults earlier this year. In June, the Advisory Committee on Immunization Practices (ACIP) for the Centers for Disease Control and Prevention (CDC) unanimously voted to recommend the 2025-2026 influenza vaccine for people aged 6 months and older. 'ACIP reaffirms the recommendations for routine annual influenza vaccination of all persons aged ≥ 6 months who do not have contraindications for the 2025-2026 season,' stated vaccine recommendations published by the CDC on Wednesday. 'With no current CDC Director and pending confirmation of a new CDC Director, this recommendation was adopted by the HHS Secretary on July 22, 2025, and is now an official recommendation of the CDC.' This vote occurred soon after Kennedy fired all sitting ACIP members and replaced them with ideological allies. In the same June meeting, the ACIP voted in favor of only recommending vaccines that don't contain the mercury-based vaccine preservative thimerosal. Vaccines without thimerosal are already widely available, with the preservative more often used in multidose vials in low-income countries. At the time of the vote, the Department of Health and Human Services publicized that the recommendation on thimerosal had been adopted but made no mention as to whether the recommendation on flu vaccines had similarly been adopted. The vote on thimerosal was not unanimous, with a minority of members arguing the evidence suggesting any harm from the substances was lacking and there were more important matters the ACIP could be looking into. Others argued that any actions that restrict access to FDA-approved vaccines should be avoided.
San Francisco Chronicle
12 minutes ago
- San Francisco Chronicle
Vroom: Q2 Earnings Snapshot
FORT WORTH, Texas (AP) — FORT WORTH, Texas (AP) — Vroom, Inc. (VRM) on Thursday reported a loss of $8.5 million in its second quarter. On a per-share basis, the Fort Worth, Texas-based company said it had a loss of $1.65. Losses, adjusted to account for discontinued operations, came to $1.73 per share. The company posted revenue of $45.7 million in the period.
